Characteristic of risk factor of thyroid cancer related metastatic bone disease at Sanglah General Hospital Denpasar between January 2013 to March 2019

Authors

  • Gede Ketut Alit Satria Nugraha Resident, Department of Orthopaedic and Traumatology, Sanglah Hospital, Faculty of Medicine, University of Udayana, Bali, Indonesia
  • I. Gede Eka Wiratnaya Consultant, Department of Orthopaedic and Traumatology, Sanglah Hospital, Faculty of Medicine, University of Udayana, Bali, Indonesia
  • Gde Dedy Andika Resident, Department of Orthopaedic and Traumatology, Sanglah Hospital, Faculty of Medicine, University of Udayana, Bali, Indonesia
  • Made Sunaria Resident, Department of Orthopaedic and Traumatology, Sanglah Hospital, Faculty of Medicine, University of Udayana, Bali, Indonesia

DOI:

https://doi.org/10.18203/2320-6012.ijrms20201337

Keywords:

Bone metastasis, Epidemiology, Thyroid cancer

Abstract

Background: Metastatic bone disease (MBD) causes a massive morbidity, pain, and disability for the sufferers. Thyroid carcinoma, which is the most common endocrine cancer worldwide, also contributes to the increased rate of MBD, as 60% of patients with thyroid carcinoma experience bone metastasis. An urgency to further analyze the risk factors of bone metastasis in thyroid cancer is necessary in order to prevent and treat this unwanted occurrence earlier and better.

Methods: A descriptive retrospective study was conducted using patients’s medical record data obtained from Sanglah General Hospital between January 2013 until March 2019. The variables obtained were sex, age, diagnosis, management, and fracture site.

Results: There were 15 patients involved in this study, presenting with pathological fracture due to MBD from thyroid cancer. Ten patients were female (66.7%)  and 5 were male (33.3%). According to the age group, 2 patients (13.3%) were <40 years old, 5 patients (33.3%) were >60 years old, while the majority of 8 patients (53.4%) were 40-60 years old. From the pathological result, 9 patients had follicular neoplasm (60%) and 5 patients had papillary neoplasm (33%). The most common site of metastasis was humerus in 7 patients (47%), while the other sites were femur, pelvic, and tibia.

Conclusions: According to this series, there are several risk factors related to MBD from thyroid carcinoma, including female gender, the age of 40-60 years old, and follicular type neoplasm. A further study with bigger amount of sample is needed to improve the result.

References

Aschebrook-Kilfoy B, Ward MH, Sabra MM, Devesa SS. Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006. Thyroid. 2011 Feb 1;21(2):125-34.

Sherman SI. Thyroid carcinoma. Lancet. 2003 Feb 8;361(9356):501-11.

Lin JD, Hsueh C, Chao TC. Long-term follow-up of the therapeutic outcomes for papillary thyroid carcinoma with distant metastasis. Med. 2015 Jul;94(26).

Zivaljevic V, Tausanovic K, Paunovic I, Diklic A, Kalezic N, Zoric G, et al. Age as a prognostic factor in anaplastic thyroid cancer. Int J Endocrinol. 2014;2014.

Liu FC, Lin HT, Lin SF, Kuo CF, Chung TT, Yu HP. Nationwide cohort study on the epidemiology and survival outcomes of thyroid cancer. Oncotarget. 2017 Oct 3;8(45):78429.

Göktaş SS. Bone Metastasis in Thyroid Cancer: A Literature Review. Otolaryngol Open Access J. 2018;3(2):1-7.

Tickoo SK, Pittas AG, Adler M, Fazzari M, Larson SM, Robbins RJ, et al. Bone metastases from thyroid carcinoma: a histopathologic study with clinical correlates. Arch Pathol Lab Med. 2000 Oct;124(10):1440-7.

Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016 Jan 1;26(1):1-33.

Gibiezaite S, Ozdemir S, Shuja S, McCook B, Plazarte M, Sheikh-Ali M. Unexpected bone metastases from thyroid cancer. Case Reports Endocrinol. 2015;2015.

Wexler JA, Sharretts J. Thyroid and bone. Endocrinology and metabolism clinics of North America. 2007 Sep 1;36(3):673-705.

Quayle L, D Ottewell P, Holen I. Bone metastasis: molecular mechanisms implicated in tumour cell dormancy in breast and prostate cancer. Curr Cancer Drug Targ. 2015 Jul 1;15(6):469-80.

Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clini Cancer Res. 2006 Oct 15;12(20):6243s-9s.

Muresan MM, Olivier P, Leclere J, Sirveaux F, Brunaud L, Klein M, Zarnegar R, Weryha G. Bone metastases from differentiated thyroid carcinoma. Endocrine-related cancer. 2008 Mar 1;15(1):37.

Sugitani I, Fujimoto Y, Yamamoto N. Papillary thyroid carcinoma with distant metastases: survival predictors and the importance of local control. Surgery. 2008 Jan 1;143(1):35-42.

Shaha AR, Ferlito A, Rinaldo A. Distant metastases from thyroid and parathyroid cancer. ORL. 2001;63(4):243-9.

Parameswaran R, Shulin Hu J, Min En N, Tan WB, Yuan NK. Patterns of metastasis in follicular thyroid carcinoma and the difference between early and delayed presentation. Ann Royal Coll Surg Engl. 2017 Feb;99(2):151-4.

Orita Y, Sugitani I, Matsuura M, Ushijima M, Tsukahara K, Fujimoto Y, et al. Prognostic factors and the therapeutic strategy for patients with bone metastasis from differentiated thyroid carcinoma. Surg. 2010 Mar 1;147(3):424-31.

Downloads

Published

2020-03-26

How to Cite

Nugraha, G. K. A. S., Wiratnaya, I. G. E., Andika, G. D., & Sunaria, M. (2020). Characteristic of risk factor of thyroid cancer related metastatic bone disease at Sanglah General Hospital Denpasar between January 2013 to March 2019. International Journal of Research in Medical Sciences, 8(4), 1430–1434. https://doi.org/10.18203/2320-6012.ijrms20201337

Issue

Section

Original Research Articles